Study of MP0112 Intravitreal Injection in Patients With Wet Age Related Macular Degeneration

Phase 1 Terminated 32 enrolled Allergan Molecular Partners AG · collab

RandomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety and tolerability of MP0112 (a novel, potentially long acting VEGF inhibitor) in patients with wet Age Related Macular Degeneration.

Timeline

Start: 2010-03
Primary completion: 2010-11
Completion: 2010-11

Outcome

Outcome not reported

Stopped: “The study was terminated due to a company decision following completion of Part A.”

Publications

Souied EH, Devin F, Mauget-Faysse M, Kolar P, Wolf-Schnurrbusch U, Framme C, Gaucher D, Querques G, Stumpp MT, Wolf S; MP0112 Study Group. Treatment of exudative age-related macular degeneration with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study. Am J Ophthalmol. 2014 Oct;158(4):724-732.e2. doi: 10.1016/j.ajo.2014.05.037. Epub 2014 Jun 5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Abicipar pegol	Protein / enzyme biologic	0.04 mg	Intravitreal
Subject	Abicipar pegol	Protein / enzyme biologic	0.15 mg	Intravitreal
Subject	Abicipar pegol	Protein / enzyme biologic	0.4 mg	Intravitreal
Subject	Abicipar pegol	Protein / enzyme biologic	1 mg	Intravitreal
Subject	Abicipar pegol	Protein / enzyme biologic	2 mg	Intravitreal
Subject	Abicipar pegol	Protein / enzyme biologic	3.6 mg	Intravitreal